A detailed history of Jpmorgan Chase & CO transactions in Ascendis Pharma A/S stock. As of the latest transaction made, Jpmorgan Chase & CO holds 39,834 shares of ASND stock, worth $4.95 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
39,834
Previous 65,262 38.96%
Holding current value
$4.95 Million
Previous $8.9 Million 33.17%
% of portfolio
0.0%
Previous 0.0%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 08, 2024

SELL
$113.0 - $153.43 $2.87 Million - $3.9 Million
-25,428 Reduced 38.96%
39,834 $5.95 Million
Q2 2024

Aug 12, 2024

BUY
$121.07 - $153.67 $4.51 Million - $5.73 Million
37,256 Added 133.03%
65,262 $8.9 Million
Q1 2024

May 10, 2024

SELL
$123.45 - $159.4 $4.18 Million - $5.4 Million
-33,858 Reduced 54.73%
28,006 $4.23 Million
Q4 2023

Feb 12, 2024

SELL
$86.1 - $127.36 $6.76 Million - $10 Million
-78,512 Reduced 55.93%
61,864 $7.79 Million
Q3 2023

Nov 14, 2023

BUY
$86.5 - $103.97 $279,481 - $335,927
3,231 Added 2.36%
140,376 $13.1 Million
Q2 2023

Aug 11, 2023

BUY
$69.96 - $97.84 $4.28 Million - $5.98 Million
61,148 Added 80.46%
137,145 $12.2 Million
Q1 2023

May 11, 2023

SELL
$104.9 - $126.78 $78,360 - $94,704
-747 Reduced 0.97%
75,997 $8.15 Million
Q4 2022

Feb 13, 2023

SELL
$99.42 - $131.97 $1.43 Million - $1.9 Million
-14,375 Reduced 15.78%
76,744 $9.37 Million
Q3 2022

Nov 14, 2022

SELL
$84.03 - $110.23 $2.78 Million - $3.65 Million
-33,092 Reduced 26.64%
91,119 $9.41 Million
Q2 2022

Aug 11, 2022

BUY
$78.08 - $117.61 $8.23 Million - $12.4 Million
105,402 Added 560.38%
124,211 $11.5 Million
Q1 2022

May 11, 2022

BUY
$102.18 - $135.75 $156,335 - $207,697
1,530 Added 8.85%
18,809 $2.21 Million
Q4 2021

Feb 10, 2022

BUY
$127.1 - $169.66 $1.31 Million - $1.75 Million
10,317 Added 148.19%
17,279 $2.32 Million
Q3 2021

Nov 12, 2021

BUY
$112.67 - $176.92 $784,408 - $1.23 Million
6,962 New
6,962 $1.11 Million

Others Institutions Holding ASND

About Ascendis Pharma A/S


  • Ticker ASND
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 55,810,200
  • Market Cap $6.94B
  • Description
  • Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapeutics for unmet medical needs. The company offers SKYTROFA for treating patients with growth hormone deficiency (GHD). It also develops TransCon Growth Hormone (hGH) for pediatric GHD in Japan; TransCon hGH for adults with GHD; TransCon parathyroid hormone for adult h...
More about ASND
Track This Portfolio

Track Jpmorgan Chase & CO Portfolio

Follow Jpmorgan Chase & CO and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Jpmorgan Chase & CO, based on Form 13F filings with the SEC.

News

Stay updated on Jpmorgan Chase & CO with notifications on news.